K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · BRISTOL-MYERS SQUIBB
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | BMY | BRISTOL-MYERS SQUIBB | THE MCMANUS GROUP | $80K | Policies related to the Most Favored Nation Drug Pricing Model Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act |
| 2026-04-20 | BMY | BRISTOL-MYERS SQUIBB | SPLITOAK STRATEGIES LLC | $60K | Value of prescription drugs and patient access Issues related to Medicaid, Medicare Parts B & D, MFN U.S. Competitiveness issues |
| 2026-04-20 | BMY | BRISTOL-MYERS SQUIBB | CAPITOL COUNSEL LLC | $40K | Issues regarding approved and pipeline products, and related policy. 340 program issues. Issues regarding approved and pipeline products, and related policy. Issues regarding approved and pipeline products, and related policy. |
| 2026-04-19 | BMY | BRISTOL-MYERS SQUIBB | CROSSROADS STRATEGIES, LLC | $0 | |
| 2026-02-25 | BMY | BRISTOL-MYERS SQUIBB | CAPITOL COUNSEL LLC | $0 | Issues regarding approved and pipeline products, and related policy. Issues regarding approved and pipeline products, and related policy. Issues regarding approved and pipeline products, and related policy. |
| 2026-01-20 | BMY | BRISTOL-MYERS SQUIBB | THE MCMANUS GROUP | $80K | Policies related to the Most Favored Nation Drug Pricing Model Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. H.R.4299 - Protecting Patient Access to Cancer and Complex Therapies Act |
| 2026-01-20 | BMY | BRISTOL-MYERS SQUIBB | SPLITOAK STRATEGIES LLC | $50K | Value of prescription drugs and patient access Issues related to Medicaid, Medicare Parts B & D H.R. 1 U.S. Competitiveness issues |
| 2026-01-20 | BMY | BRISTOL-MYERS SQUIBB | CROSSROADS STRATEGIES, LLC | $40K | General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation. Issues related to tax reform; R&D tax credit; international taxation. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and PBM reform; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. |
| 2025-10-20 | BMY | BRISTOL-MYERS SQUIBB | THE MCMANUS GROUP | $80K | |
| 2025-10-20 | BMY | BRISTOL-MYERS SQUIBB | CROSSROADS STRATEGIES, LLC | $40K | Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and PBM reform; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. H.R.1, One Big Beautiful Bill Act (P.L.119-21), all bio-pharmaceutical related provisions. Issues related to tax reform; R&D tax credit; international taxation; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21). Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to pharmaceu |
| 2025-10-20 | BMY | BRISTOL-MYERS SQUIBB | SPLITOAK STRATEGIES LLC | $40K | Value of prescription drugs and patient access Issues related to Medicaid, Medicare Parts B & D H.R. 1 |
| 2025-10-11 | BMY | BRISTOL-MYERS SQUIBB | SPLITOAK STRATEGIES LLC | $50K | Value of prescription drugs and patient access Issues related to Medicare Parts B & D Implementation of P.L. 117-659 (H.R.5376) - Inflation Reduction Act |
| 2025-07-28 | BMY | BRISTOL-MYERS SQUIBB | THE MCMANUS GROUP | $0 | General issues related to pharmaceuticals |
| 2025-07-21 | BMY | BRISTOL-MYERS SQUIBB | CROSSROADS STRATEGIES, LLC | $40K | H.R.1, One Big Beautiful Bill Act, all bio-pharmaceutical related provisions. Issues related to tax reform; R&D tax credit; international taxation; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act. Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues. Issues related to pharmaceutical IP, supply chain, and tariffs. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and PBM reform; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) imple |
| 2025-07-21 | BMY | BRISTOL-MYERS SQUIBB | SPLITOAK STRATEGIES LLC | $10K | Value of prescription drugs and patient access Issues related to Medicaid, Medicare Parts B & D H.R. 1 H.R.946/S.1862 - ORPHAN Cures Act |
| 2025-04-21 | BMY | BRISTOL-MYERS SQUIBB | CROSSROADS STRATEGIES, LLC | $40K | Issues related to pharmaceutical IP, supply chain, and tariffs. Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, and PBM reform; Inflation Reduction Act of 2022 (P.L.117-169) implementation; S.891, Bipartisan Health Care Act. General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation. H.R.1968, Full-Year Continuing Appropriations and Extensions Act, 2025 (P.L.119-4); H.Con.Res.14, FY2025 Budget Resolution; FY2025 Budget Reconciliation Process; all bio-pharmaceutical related provisions. Issues related to tax reform. Inflation Reduction Act of 2022 (P.L.117-169) implementation; issues related to international taxation. Issues related to R&D tax credit. Biopharmaceutical innovation and patent policy issue |
| 2025-04-21 | BMY | BRISTOL-MYERS SQUIBB | SPLITOAK STRATEGIES LLC | $0 | |
| 2025-01-21 | BMY | BRISTOL-MYERS SQUIBB | SPLITOAK STRATEGIES LLC | $50K | Value of prescription drugs and patient access Issues related to Medicare Parts B & D Implementation of P.L. 117-659 (H.R.5376) - Inflation Reduction Act |